301 results about "Fatty liver" patented technology

The invention belongs to the field of traditional Chinese medicines, and relates to a traditional Chinese medicine composition for treating liver depression and spleen deficiency syndrome metabolism-related fatty liver disease, which is prepared from the following raw materials in parts by weight: 8 to 10 parts of ginseng, 10 to 15 parts of radix bupleuri, 10 to 15 parts of radix curcumae, 6 to 9 parts of ginger processed pinellia, 6 to 10 parts of fructus amomi, 10 to 15 parts of rhizoma atractylodis, 10 to 15 parts of poria cocos, 10 to 15 parts of semen hoveniae, 10 to 15 parts of radix rehmanniae, 8 to 10 parts of rhizoma polygoni cuspidati and 6 to 9 parts of lignum dalbergiae odoriferae. The traditional Chinese medicine composition is used for treating the metabolism-related fatty liver diseases from the aspects of liver depression, spleen deficiency and phlegm-blood stasis, starts from the core pathological chain of liver depression, spleen deficiency, phlegm-dampness and blood stasis, has the functions of soothing the liver, tonifying the spleen, resolving dampness, reducing fat and promoting blood circulation to remove meridian obstruction, and is particularly suitable for patients with liver depression, spleen deficiency and metabolism-related fatty liver diseases. Clinical tests prove that the traditional Chinese medicine composition has a good treatment effect on patients with liver depression and spleen deficiency syndrome metabolism-related fatty liver diseases, the total effective rate reaches 94% or above, and the traditional Chinese medicine composition is mild in medicine property, good in safety, stable in curative effect, not prone to relapse and suitable for being taken for a long time.

The invention belongs to the technical field of biological pharmacy, and provides an application of jonquil glucoside in preparation of a medicine for treating a metabolism-related fatty liver disease, and the application is that the jonquil glucoside is applied to preparation of the medicine for treating the metabolism-related fatty liver disease. The treatment effect of the jonquil glycoside on MASLD is evaluated by adopting a method for establishing a fatty liver model through induction of HFD high-fat, high-fructose and high-cholesterol feed. Results show that the jonquil glucoside can reduce the liver weight by inhibiting weight gain, reduce the content of TC and TG in serum, improve the conditions of liver inflammation and fat change, reduce the oxidative stress level of liver tissue and restore SIRT1 protein expression of the liver tissue to achieve the purpose of treating MASLD.

The present invention relates to the use of an ROR inverse agonist or a pharmaceutically acceptable salt thereof for the preparation of a medicament for modulating ROR in a patient and / or for controlling autoimmune diseases and antibody-mediated rejection in a patient. The ROR-mediated diseases or autoimmune diseases include HIV, cancer, celiac disease, type 1 diabetes, Graves' disease (Graves' disease), inflammatory bowel disease, multiple sclerosis, psoriasis, rheumatoid arthritis, systemic lupus erythematosus, asthma, dermatitis, fatty liver disease, Crohn's disease (Crohn's disease), cardiovascular disease, inflammatory disease, nervous system disorders, multiple sclerosis, and the like. Acute respiratory distress syndrome and arteriosclerosis.

The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine composition with an effect of preventing and treating alcoholic liver injury as well as a preparation method and application thereof. The traditional Chinese medicine composition is prepared from the following raw material medicines: radix puerariae, turmeric, ginseng, hovenia dulcis thunb, white hyacinth bean, raw oyster shell, poria cocos, raw hawthorn, biond magnolia flower, juncus effuses and albizia flower. The traditional Chinese medicine composition has the effects of soothing liver and harmonizing stomach, dispelling alcohol effect and enlivening spleen, and reinforcing qi and nourishing blood. Experimental results show that the traditional Chinese medicine composition has a good treatment effect on acute alcoholic liver injury and chronic alcoholic fatty liver, and can effectively improve the symptoms of chest rib swelling pain, reduced appetite, anorexia, abdominal distension, hiccup, belching, borborygmus and qi and loose stool caused by liver-stomach disharmony and spleen deficiency and dampness of alcoholic liver injury patients; therefore, the method has good development and utilization prospects.

The invention belongs to the technical field of biological medicine, and discloses a pharmaceutical composition for treating metabolic diseases, a preparation method and application, and the pharmaceutical composition comprises edaravone or pharmaceutically acceptable salts thereof and dextroborneol. The weight ratio of the edaravone to the dextroborneol is (10: 1)-(1: 1). The invention finds that the combination of edaravone and dextroborneol shows remarkable curative effects in the aspects of improving cognitive function, reducing blood fat, relieving fatty liver and recovering cardiac function and / or overall metabolic homeostasis; meanwhile, the pharmaceutical composition disclosed by the invention has a remarkable comprehensive treatment effect on metabolic diseases or complications (such as metabolic syndrome) of the metabolic diseases and / or vascular cognitive impairment complicated with the metabolic syndrome.

The present invention relates to methods for treating overweight or obese in individuals in need thereof, and / or individuals with fatty liver disease or diabetes. In particular, the present invention relates to a method of treating obesity, fatty liver disease or diabetes in an individual in need thereof, the method comprising administering a SIK-3 inhibitor and a metabolic modulator to the individual.

The present invention relates to the preventive, alleviative, or therapeutic effects of an extract of Cucumis melo var. makuwa leaves, particularly an alcoholic extract of Cucumis melo var. makuwa leaves, on fatty liver disease associated with metabolic dysfunction. The extract of Cucumis melo var. makuwa leaves according to the present invention can reduce liver weight and the accumulation of fat in liver tissue, and can significantly inhibit ALT activity in the blood, and thus can provide an effective fatty liver prevention, alleviation, or treatment effect. In addition, the extract of Cucumis melo var. makuwa leaves according to the present invention has a high yield of about 21% and thus may be highly economical as an excellent material for preventing, alleviating or treating fatty liver disease.

The invention discloses a 3-hydroxyisovaleric acid and guaiacol composition and application of the 3-hydroxyisovaleric acid and guaiacol composition in preparation of a medicine for treating or preventing glucose metabolism disorder. The invention provides a strategy for treating metabolic diseases by combining 3-hydroxyisovaleric acid and guaiacol for the first time. It is found that combination of the two has a significant synergistic effect, and combination of low doses is superior to single use of high doses. Systematic animal experiments prove that the traditional Chinese medicine composition has a remarkable effect of improving blood sugar, insulin resistance and fatty liver.

The utility model provides a fatty liver sample storage device, which relates to the technical field of storage devices, and comprises a refrigeration box body, a plurality of clapboards are equidistantly arranged in the refrigeration box body from the right upper part to the lower part, a plurality of fixing mechanisms are equidistantly arranged at the top ends of the clapboards, and each fixing mechanism comprises a base. The base is fixedly installed at the top end of the partition plate, a buffering assembly is installed in the base, a fixing base is fixedly connected to the back face of the base, a pressing assembly is arranged in the fixing base, and clamping assemblies are symmetrically installed in the fixing base and located on the left side and the right side of the pressing assembly; according to the fatty liver sample storage device, the base, the buffering assembly, the fixing base, the pressing assembly and the clamping assembly are used in cooperation, test tubes loaded with fatty liver samples can be stably placed, meanwhile, rapid placing and taking work can be achieved, compared with a traditional storage device, the placing and taking stability is greatly improved, and practicability is effectively improved.

The invention discloses liquiritigenin and isoliquiritigenin produced by directionally converting liquiritin and isoliquiritigenin through lactobacillus plantarum CCFM1275 and application of the liquiritigenin and the isoliquiritigenin. Researches show that the lactobacillus plantarum CCFM1275 can grow in a fermentation base material rich in a licorice extract, and liquiritin and isoliquiritin in licorice can be converted into liquiritigenin and isoliquiritigenin respectively, so that utilization of active ingredients of liquiritin and isoliquiritigenin by an organism is facilitated, and the effect of the licorice extract is improved. Compared with the licorice root extract, the fermented licorice root postbiotics obtained by fermenting and converting the licorice root extract through the lactobacillus plantarum CCFM1275 can further improve the effects of the licorice root extract in the aspects of reducing liver lipid accumulation, lowering lipid and resisting aging, can be used for preparing products with the effects of preventing and / or treating fatty liver and obesity and / or resisting aging, and has a huge application prospect.

The invention relates to the field of medicines, and discloses a novel human PYY analogue, and compared with a PYY3-36 natural sequence, the novel human PYY analogue has a remarkable effect on improving metabolic diseases such as obesity, diabetes and fatty liver and emotional diseases such as anxiety disorder and depression.

The present application relates to novel substituted indazoles, to processes for preparation thereof, to the use thereof alone or in combinations for treatment and / or prophylaxis of diseases, and to the use thereof for production of medicaments for treatment and / or prophylaxis of diseases, especially for treatment and / or prophylaxis of endometriosis and endometriosis-associated pain and other endometriosis-associated symptoms such as dysmenorrhoea, dyspareunia, dysuria and dyschezia, of lymphoma, rheumatoid arthritis, spondyloarthritis (especially psoriatic spondyloarthritis and Bekhterev's disease), lupus erythematosus, multiple sclerosis, macular degeneration, COPD, gout, fatty liver disorders, insulin resistance, neoplastic disorders and psoriasis.

This invention discloses a gRNA combination and its application in the preparation of drugs for the prevention of metabolic-associated fatty liver disease (MASLD). The gRNA combination, when mixed with Cas9 protein, yields an RNP complex, which, when microinjected into mouse zygotes, can breed a stable and heritable mouse strain with TMEM68 gene knockout. Combining lipidomics, transcriptomics, and primary hepatocyte functional verification, the core regulatory role of TMEM68 in hepatic lipid metabolism is revealed for the first time systematically. Experiments demonstrate that TMEM68 deficiency significantly reduces the storage of triglycerides (TAG) in the liver and hepatocytes, decreases lipid droplet formation, and reshapes the metabolic homeostasis of various lipids such as glycerophospholipids, cholesterol esters, and bile acids. Therefore, the gRNA combination of this invention, or the RNP complex obtained by mixing the gRNA combination with Cas9 protein, can be used to prepare drugs for the prevention of MASLD, providing a novel intervention strategy for MASLD prevention with broad application prospects.

The application belongs to the field of genetic engineering and biosynthesis, and particularly relates to biosynthesis of a class of diterpenoids. The application provides genes having a key role in the formation of a 5-8-5 tricyclic mother nucleus and a five-membered heterocyclic ring in biosynthesis of the class of diterpenoids, which are respectively named as PrcA and PrcB and polypeptides encoded by the genes, expression of PrcA and PrcB is carried out through a heterologous expression system of Aspergillus oryzae, and five diterpenoids with novel structures and anti-metabolic related fatty liver disease activity are obtained. The application provides application of the polypeptides in biosynthesis of the class of diterpenoids, and enriches a diterpenoid library, thereby providing lead compound resources for discovering new anti-metabolic related fatty liver disease medicinal raw materials.

The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a traditional Chinese medicine composition with hangover-alleviating and liver-protecting effects and a preparation method and application thereof. The traditional Chinese medicine composition is prepared from the following raw material medicines: semen hoveniae, flos puerariae, rhizoma gastrodiae, pericarpium citri reticulatae, poria cocos, rhizoma alismatis, herba artemisiae scopariae, gynostemma pentaphylla, roasted rhizoma atractylodis macrocephalae, cortex magnoliae officinalis, radix paeoniae alba and honey-fried licorice root. The traditional Chinese medicine composition disclosed by the invention has the effects of relieving alcoholism, resolving damp turbidity, clearing liver and gallbladder and strengthening spleen soil. The traditional Chinese medicine composition disclosed by the invention is particularly suitable for patients suffering from alcohol fever, alcoholic liver, hyperlipidemia and liver and gall diseases mainly caused by damp turbidity and alcohol toxicity. Experimental results show that the traditional Chinese medicine composition has a good treatment effect on acute alcoholic liver injury and chronic alcoholic fatty liver, so that the traditional Chinese medicine composition has a relatively good development and utilization prospect.

This invention relates to the field of biomedical technology, specifically to HCBP6 monoclonal antibodies and their applications. This invention utilizes bioinformatics databases and online tools to analyze the structure of the HCBP6 protein, screening for highly immunogenic HCBP6 antigen peptides. Antibody 1 and Antibody 2 are obtained through immunization. The combination of Antibody 1 and Antibody 2 is used for the detection of HCBP6, exhibiting high sensitivity and good detection results. It has significant development and application value and long-term implications for the auxiliary diagnosis of fatty liver.

The invention discloses a machine learning spectral clustering analysis method and system for fatty liver auxiliary screening. Comprising the following steps: acquiring medical data and a fatty liver diagnosis result, and preprocessing and standardizing the medical data to obtain a training data set; reversely searching an optimal feature combination from a plurality of data indexes through an enumeration method; training the fatty liver auxiliary analysis model based on the spectral clustering algorithm by using the training data only containing the optimal feature combination; and obtaining a fatty liver auxiliary analysis result by using the trained fatty liver auxiliary analysis model. The method is used for early-stage rapid screening of the fatty liver diseases, the classification accuracy and auxiliary diagnosis efficiency of the fatty liver diseases are improved, and high calculation cost is not needed.

The invention provides application of a xanthine derivative in preparation of a medicine for preventing and / or treating fatty liver diseases related to metabolic dysfunction, and belongs to the technical field of medicine preparation. The invention relates to an application of a xanthine derivative 8-[(2, 3-dihydroxy propyl) sulfo]-3-methyl-7-[(4-methylphenyl) methyl]-1H-purine-2, 6-diketone in preparation of a medicine for preventing and / or treating fatty liver diseases related to metabolic dysfunction. The xanthine derivative has dual efficacy of improving liver cell insulin sensitivity and / or reducing liver cell lipid accumulation, and provides a new way for treatment of metabolic dysfunction related fatty liver diseases and preparation of related clinical drugs.

The invention provides an organoid culture medium, an organoid culture method and application of the organoid culture medium, the organoid culture medium comprises a first-stage culture medium, the first-stage culture medium comprises a first-stage basic culture medium and first-stage addition factors, and the first-stage addition factors comprise N-acetylcysteine, nicotinamide, a ROCK inhibitor, Noggin, R-spondin, EGF, HGF, Gastrin, FGF10, Blebbistatin, Forskolin, A83-01, LDN193189, DAPT, TGF-alpha and UDAC. By using the organoid culture medium, the liver organoid and the fatty liver organoid can be effectively obtained, and the obtained fatty liver organoid has obvious fat deposition, is sensitive to fatty liver treatment drugs, highly restores the physiological status when human body fatty liver diseases occur, and has high application value.

The invention belongs to the technical field of functional compositions, and discloses a composition for dispelling effects of alcohol and protecting liver as well as a preparation method and application thereof, and the composition comprises the following raw materials in percentage by mass: 13-28% of ginseng, 18-28% of globe artichoke, 10-27% of pueraria peptide, 7-12% of houttuynia cordata, 7-9% of mulberry, 6-9% of gardenia and 10-29% of collagen composite peptide. The composition can reduce alcohol irritation, relieve alcohol absorption and increase the alcohol content; meanwhile, the liver and stomach are protected; meanwhile, alcohol metabolism is rapid, hangover is prevented, headache, dizziness, nausea and other uncomfortable symptoms caused by alcohol are relieved, and the drunkenness degree is relieved. After the medicine is taken for 2-6 months, mild fatty liver and moderate fatty liver can be obviously improved, and severe fatty liver and alcoholic liver can be obviously improved; indexes related to endocrine metabolism, such as blood sugar, blood fat, uric acid, triglyceride, total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, glutamic oxalacetic transaminase and glutamic-pyruvic transaminase, are obviously improved.

The present invention relates to the technical field of liver-protecting formula compositions, and in particular, to a liver-protecting milk thistle formula composition, and a preparation method thereof. Technical problems: the liver-protecting milk thistle formula composition, and a preparation method thereof are intended to solve the technical problems that most of existing liver-protecting compositions in the prior art are designed for the general liver protection needs of the general population and cannot specifically treat liver damage caused by excessive alcohol intake and liver diseases such as cirrhosis, acute hepatitis, hepatitis, fatty liver, cholangitis, cholelithiasis, psoriasis, and hypercholesterolemia. Technical solution: a liver-protecting milk thistle formula composition, including the following components: silymarin, puerarin, artichoke extract, glutathione, dandelion extract, and GABA. The liver-protecting formula composition has a good therapeutic effect on liver damage caused by excessive alcohol intake, and liver diseases such as cirrhosis, acute hepatitis, hepatitis, fatty liver, cholangitis, cholelithiasis, psoriasis, and hypercholesterolemia.

The present invention relates to a composition for preventing, alleviating or treating metabolic diseases, the composition comprising a rosuvastatin and ursodeoxycholic acid conjugate or a pharmaceutically acceptable salt thereof, in which the statin conjugates to an ursodeoxycholic acid transporter and has the effects of function inhibition, cholesterol level reduction, antilipid toxicity, body weight reduction, blood lipid reduction, fatty liver alleviation, inflammation alleviation, and kidney damage alleviation. The composition, in the form of a single formulation, has the characteristics of maintaining the therapeutic effects of rosuvastatin and ursodeoxycholic acid while reducing the side effects of existing statins, and thus can be widely used as a substitute for complex formulations in the treatment of metabolic diseases.

The invention relates to an application of a silybum marianum extract for improving, preventing or treating fatty liver, wherein the bioavailability of silymarin is improved. In the present invention, a silybum marianum extract of the present invention having improved bioavailability is prepared by subjecting silybum marianum seeds to enzyme treatment and low-concentration ethanol solvent extraction, and it is confirmed that the silybum marianum extract of the present invention has high bioavailability and exhibits excellent efficacy in improving, preventing or treating fatty liver.

Provided herein are anti-Activin E antibodies having specific complementarity determining regions (CDRs) for the heavy and light chains, heavy and light chains, antigen binding fragments thereof, polynucleotides that encode the same, vectors, and host cells, and methods for treating a metabolic disorder, type 2 diabetes, obesity, an elevated triglyceride level, lipodystrophy, liver inflammation, fatty liver disease, hypercholesterolemia, an elevated liver enzyme, nonalcoholic steatohepatitis (NASH), a cardiovascular disease, cardiomyopathy, high blood pressure, and / or heart failure with the anti-Activin E antibodies disclosed herein.

The invention provides a composition containing a white peony root extract, a Chinese magnoliavine fruit extract, a pomegranate extract and a ginseng extract. The composition or the nutritional supplement and the pharmaceutical composition containing the composition can obviously promote the expression of the individual glycine-N-methyltransferase, so that the composition can be applied to nutritional supplement or pharmaceutical products for resisting aging, fatty liver or liver cancer and the like.

The present disclosure discloses a composition of GLP-1 and PYY3-36 polypeptide analogues, a preparation method and use thereof, and relates to the technical field of biomedicines. The composition includes a GLP-1 polypeptide analogue and a PYY3-36 polypeptide analogue. Compared with the natural sequence of GLP-1 and the natural sequence of PYY3-36, the composition of the GLP-1 polypeptide analogue and the PYY3-36 polypeptide analogue has remarkable effects in ameliorating metabolic diseases such as obesity, diabetes mellitus, and fatty liver, and mood disorders such as anxiety and depression.

This invention belongs to the technical field of natural product active ingredients, specifically relating to a glycopeptide LBGP-I-b derived from wolfberry and its uses. The glycopeptide LBGP-I-b has an average molecular weight of 700–1000 Da, a polypeptide content of 70%–80%, and a polysaccharide content of 10%–20%. The sugar chains are composed of glucose residues, and the sugar chains are linked to the peptide chains via O-glycopeptide bonds. The glycopeptide has functions such as regulating lipid metabolism, lowering blood lipid levels, and improving liver function. The glycopeptide of this invention has a clear source and stable properties, and has good application prospects in the prevention and treatment of metabolic diseases such as metabolic-related fatty liver disease.

The present application provides a novel thyroid hormone β receptor agonist of formula (I) having better activity, selectivity or safety and the use thereof for preventing or treating diseases related to the action of β receptor agonists, including, for example, obesity, hyperlipidemia, hypercholesterolemia, diabetes, liver diseases (fatty liver, NASH, NAFLD, etc.), cardiovascular diseases (atherosclerosis, etc.), thyroid diseases (hypothyroidism, thyroid cancer, etc.), and the like.